Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

Trial Details

NCT ID

NCT05997017

Phase

PHASE2

Sponsor

Aadi Bioscience, Inc.

Status

RECRUITING

Cancer Type

Uterine Cancer

Interventions

• nab-sirolimus

Locations (sample)

• Little Rock, Arkansas, United States|34.74648,-92.28959
• Miami Beach, Florida, United States|25.79065,-80.13005
• Las Vegas, Nevada, United States|36.17497,-115.13722
• New York, New York, United States|40.71427,-74.00597
• Charlotte, North Carolina, United States|35.22709,-80.84313

Key Eligibility Criteria

• Patients must have clinically confirmed advanced or recurrent endometrioid endometrial carcinoma. Histologic documentation of the recurrence is sug…
• All patients must have 1 or more measurable target lesion at baseline by computed tomography (CT; or magnetic resonance imaging \[MRI\] if CT scans…
• Patients must have EEC that is metastatic or locally advanced where surgical resection is not an option or likely to result in severe morbidity.
• Prior treatment history:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.